Targeting chronic lymphocytic leukemia cells in the tumor microenviroment:A review of the in vitro and clinical trials to date

Kyle Crassini; Stephen P Mulligan; O Giles Best

首页> 中文期刊> 《世界临床病例杂志》 >Targeting chronic lymphocytic leukemia cells in the tumor microenviroment:A review of the in vitro and clinical trials to date

Targeting chronic lymphocytic leukemia cells in the tumor microenviroment:A review of the in vitro and clinical trials to date

开具论文收录证明 >>

期刊封面封底目录下载 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Chronic lymphocytic leukemia(CLL)is the most common leukemia in the western world.Despite significant advances in therapy over the last decade CLL remains incurable.Current front-line therapy often consists of chemoimmunotherapy-based regimens,most commonly the fludarabine,cyclophosphamide plus rituximab combination,but rates of relapse and refractory disease are high among these patients.Several key signaling pathways are now known to mediate the survival and proliferation of CLL cells in vivo,the most notable of which are the pathways mediated by the B-cell receptor(BCR)and cytokine receptors.A better understanding of the pathogenesis of the disease,the underlying biology of the CLL-cell and the roles of the tumour microenvironment has provided the rationale for trials of a range of novel,more targeted therapeutic agents.In particular,clinical trials of ibrutinib and idelalisib,which target the Brutons tyrosine kinase and the delta isoform of phosphoinositol-3 kinase components of the BCR signaling pathway respectively,have shown extremely promising results.Here we review the current literature on the key signaling pathways and interactions of CLL cells that mediate the survival and proliferation of the leukemic cells.For each we describe the results of the recent clinical trials and in vitro studies of novel therapeutic agents.

著录项

来源
《世界临床病例杂志》 |2015年第8期|P.694-704|共11页
作者
Kyle Crassini; Stephen P Mulligan; O Giles Best;
展开▼
作者单位

[1]Northern Blood Research Centre and CLL Australian Research Consortium;

Kolling Institute of Medical Research;

Royal North Shore Hospital;

Sydney NSW 2065;

Australia;

[1]Northern Blood Research Centre and CLL Australian Research Consortium;

Kolling Institute of Medical Research;

Royal North Shore Hospital;

Sydney NSW 2065;

Australia;

[1]Northern Blood Research Centre and CLL Australian Research Consortium;

Kolling Institute of Medical Research;

Royal North Shore Hospital;

Sydney NSW 2065;

Australia;

展开▼
原文格式 PDF
正文语种 CHI
中图分类医药、卫生;
关键词
Chronic lymphocytic leukemia; Therapy; Microenvironment; Leukemia; Novel;

相似文献

中文文献
外文文献
专利

Targeting chronic lymphocytic leukemia cells in the tumor microenviroment:A review of the in vitro and clinical trials to date

摘要

著录项

相似文献

相关主题

期刊订阅